Description
ABT-702 (hydrochloride) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 (hydrochloride) shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 (hydrochloride) attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 (hydrochloride) shows analgesic and anti-inflammatory effects in vivo. ABT-702 (hydrochloride) can be used for diabetic retinopathy research[1][2][3]